Compare Cenovus Energy Inc (CVE) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Cytokinetics Inc — how do they compare? Cenovus Energy Inc trades at $31.4 (market cap $57.90B), while Cytokinetics Inc trades at $61.95 (market cap $8.62B). The key difference: Cenovus Energy Inc is far larger — about 6.7× Cytokinetics Inc's market cap, and Cenovus Energy Inc pays a 1.97% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Cytokinetics Inc for 19 Days on average.
| CVE | CYTK | |
|---|---|---|
Market Cap | $57.90B | $8.62B |
Volume | 7,863,588 | 2,594,626 |
Sector | Energy | Health |
52-Week High | $33.92 | $87.26 |
52-Week Low | $15.85 | $54.76 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $63.84B | $8.72B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 20.96% ROE and 11.48% net margin, supported by recent earnings beats. Cash flow trends indicate operational strength, though net cash flow was negative $353 million in 2025. Analyst sentiment is mixed with 40.74% buy ratings, while recent news highlights growth potential and value attributes.
Outlook: CVE offers value with a low P/E of 12.43 and solid earnings growth projections, but faces headwinds from volatile oil prices and mixed technical indicators. Risks include energy market fluctuations and debt levels, though institutional interest remains steady. The stock presents a balanced opportunity for value investors seeking energy exposure.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
